- Home
- WWW vs NRIX Comparison
WWW vs NRIX Comparison
Compare WWW & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WWW | NRIX |
|---|---|---|
| Founded | 1883 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2001 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WWW | NRIX |
|---|---|---|
| Price | $16.07 | $15.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $24.44 | ★ $30.58 |
| AVG Volume (30 Days) | ★ 1.2M | 891.7K |
| Earning Date | 05-07-2026 | 04-10-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 96.55 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $1,874,300,000.00 | $76,987,000.00 |
| Revenue This Year | $6.71 | N/A |
| Revenue Next Year | $5.95 | $26.32 |
| P/E Ratio | $14.45 | ★ N/A |
| Revenue Growth | 6.80 | ★ 99.31 |
| 52 Week Low | $9.58 | $8.18 |
| 52 Week High | $32.80 | $22.50 |
Technical Indicators
Market Signals| Indicator | WWW | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 44.95 |
| Support Level | $15.69 | $14.91 |
| Resistance Level | $19.28 | $16.47 |
| Average True Range (ATR) | 0.63 | 0.83 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 18.27 | 47.03 |
Price Performance
Historical ComparisonAbout WWW Wolverine World Wide Inc.
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Corporate and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.